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ABSTRACT 
Sulfonylureas, a commonly-used class of medication used to treat type 2 diabetes, have 
been associated with an increased risk of cardiovascular disease. Their effects on QT 
interval duration and related electrocardiographic phenotypes are potential mechanisms 
for this adverse effect. In eleven ethnically diverse cohorts that included 71 857 
European, African American, and Hispanic/Latino ancestry individuals with repeated 
measures of medication use and electrocardiogram (ECG) measurements, we 
conducted a pharmacogenomic genome-wide association study of sulfonylurea use and 
three ECG phenotypes: QT, JT, and QRS intervals. In ancestry-specific meta-analyses, 
8 novel pharmacogenomic loci met the threshold for genome-wide significance (P < 5 x 
10-8), and a pharmacokinetic variant in CYP2C9 (rs1057910) that has been associated 
with sulfonylurea-related treatment effects and other adverse drug reactions in previous 
studies was replicated. Additional research is needed to replicate the novel findings and 
to understand their biological basis. 
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INTRODUCTION 
 
Sulfonylureas are the oldest class of oral glucose-lowering therapy used to treat type 2 
diabetes, and despite the emergence of several new classes of diabetes drugs in recent 
years,1 sulfonylureas remain the most widely prescribed oral therapy after metformin.2 
Since the University Group Diabetes Program trial found that the first-generation 
sulfonylurea chlorpropamide increased the risk of cardiovascular mortality over 40 years 
ago,3 there have been concerns about the cardiovascular safety of sulfonylureas. 
Several studies since then have found that treatment with sulfonylureas is associated 
with an increased risk of cardiovascular events and mortality compared with other 
glucose-lowering drugs.4, 5 
 
As one potential mechanism of cardiovascular toxicity, sulfonylureas can prolong the 
QT interval,6, 7 a marker of cardiac repolarization that is associated with fatal 
arrhythmias and sudden cardiac death.8-12 Indeed, QT prolongation has been one of the 
most common safety issues leading to drug withdrawals from the market.13, 14 Since 
2005, the Food and Drug Administration has required clinical studies to evaluate 
whether a new drug prolongs the QT interval greater than 5 millisecond (ms) prior to 
regulatory approval.15 
 
Variation in the QT interval is heritable,16, 17 and large scale genome-wide association 
(GWA) studies have identified at least 35 genetic loci associated with this trait, which 
collectively explain about 10% of inter-individual variation in the QT interval.18 
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Pharmacogenomic studies of sulfonylurea use and the QT interval may help to unravel 
the biologic mechanisms underlying the cardiovascular toxicity of sulfonylureas. 
However, previous pharmacogenomic studies of the glucose-lowering or adverse 
effects of sulfonylureas have been small and focused on candidate genes,19-22 and most 
findings have not replicated.23, 24 In the Cohorts for Heart and Aging Research in 
Genomic Epidemiology (CHARGE) Consortium Pharmacogenomics Working Group, a 
previous GWA study of sulfonylurea-QT interactions that included approximately 30 000 
European ancestry individuals with cross-sectional measures of drug use and the QT 
interval did not identify any pharmacogenomic loci at genome-wide levels of 
significance.25 
 
To increase our power to identify novel pharmacogenomic loci for sulfonylureas, we 
extended this effort to include several additional diverse-ancestry cohorts with a high 
prevalence of sulfonylurea use. Additionally, we incorporated repeated measures of 
drug exposure and phenotype with novel analytic methods.26 Because genetic variants 
can have different effects on the two components of the QT interval27 -- the JT interval, 
which measures primarily repolarization, and the QRS interval, which measures 
primarily conduction and depolarization -- we also extended our analyses to include 
them. 
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METHODS 
 
Study Population and Overview 
 
Eleven cohorts participated in this meta-analysis from the CHARGE28 
Pharmacogenomics Working Group: Age, Gene/Environment Susceptibility – Reykjavik 
Study (AGES); Atherosclerosis Risk in Communities (ARIC) Study; Cardiovascular 
Health Study (CHS); Health, Aging, and Body Composition (Health ABC); Hispanic 
Community Health Study/Study of Latinos (HCHS/SOL); Jackson Heart Study (JHS); 
Multi-Ethnic Study of Atherosclerosis (MESA); Netherlands Epidemiology of Obesity 
(NEO) Study; Prospective Study of Pravastatin in the Elderly at Risk (PROSPER); 
Rotterdam Study cohorts 1 and 2; and the Women’s Health Initiative (WHI) 
(Supplementary Text). Cohorts contributed results from European ancestry (EA), 
African American (AA), and/or Hispanic/Latino ancestry (HA) populations. All cohorts 
had at least one study visit with an assessment of medication use and a resting 12-lead 
electrocardiogram (ECG); AGES, ARIC, CHS, the Rotterdam Study, MESA, and WHI 
had multiple study visits with these assessments and contributed repeated measures. 
Each cohort followed a pre-specified analysis protocol, and findings from within-cohort 
analyses were combined in three sets of ancestry-specific meta-analyses (EA, AA, HA) 
for three ECG phenotypes (QT, JT, and QRS intervals), for a total of nine primary 
analyses. All available cohorts were included in this single discovery effort, rather than a 
two-stage design with discovery and replication, to improve our power to identify 
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significant pharmacogenomic interactions.29, 30 This study was approved by the 
institutional review board of each cohort. 
 
Inclusion and Exclusion Criteria 
 
Participants with genome-wide genotype data and with ECG measurements and 
medication assessments at the same study visits were eligible. The following exclusion 
criteria were applied: poor ECG quality; atrial fibrillation; second or third degree 
atrioventricular heart block; QRS interval > 120 ms; a paced rhythm; history of heart 
failure; pacemaker implantation; pregnancy; and ancestry other than European, African 
American, or Hispanic/Latino. For studies with repeated measures, exclusion criteria 
were applied for each visit-specific observation. 
 
Drug Exposure Assessment 
 
Sulfonylurea drugs are listed in Supplementary Table 1. Sulfonylurea use was assessed 
through medication inventories conducted at study visits, or using information from a 
pharmacy database for the Rotterdam Study (Supplementary Table 2). Some cohorts 
assessed medication use on the day of the study visit, while others assessed 
medication use within an interval of time prior to the study visit, typically 2 weeks. For 
cohorts with repeated measures, the number of participants exposed to sulfonylureas 
(Nexposed) was the sum of the estimated number of independent observations at which 
each participant was exposed, calculated from the following equation: 
Page 11 
 
Nexposed =
ni
1+ ni -1( ) rˆ
# Eit =1{ }
nii
å  
where the summand is the product of the estimated number of independent 
observations and the proportion of observations at which a participant was exposed,31 
with ni being the number of observations for participant i, rˆ  an estimate of the pairwise 
visit-to-visit correlation in outcome within participants from a generalized estimating 
equation (GEE)-exchangeable model that does not contain genetic data, and # Eit =1{ } 
the number of observations for which participant i was exposed.26  
 
Phenotype Measurement 
 
QT and QRS intervals were recorded from resting, supine or semi-recumbent, standard 
12-lead ECGs (Supplementary Table 2). Across all cohorts, comparable procedures 
were used for preparing participants, placing electrodes, recording, transmitting, 
processing, and controlling the quality of ECGs. Cohorts used Marquette MAC 5000, 
MAC 1200, or MAC PC (GE Healthcare, Milwaukee, Wisconsin, USA), Burdick Eclips 
850i (Cardiac Science, Manchester, UK), or ACTA (EASOTE, Florence, Italy) machines. 
Recordings were processed using Marquette 12SL, MEANS, or University of Glasgow 
software. The JT interval was calculated by the formula: JT = QT – QRS. 
 
Genotyping and Imputation 
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All cohorts performed genome-wide genotyping with either Affymetrix (Santa Clara, CA, 
USA) or Illumina (San Diego, CA, USA) arrays, and used similar quality control 
thresholds for excluding samples and single nucleotide polymorphisms (SNPs) 
(Supplementary Table 3). Sex mismatches, duplicate samples, and first-degree 
relatives (except in HCHS/SOL and JHS) were excluded. DNA samples and SNPs with 
call rates less than 90-98%, depending on the cohort, were excluded. Within each 
cohort, SNPs with minor allele frequencies (MAF) less than 1% or that failed Hardy-
Weinberg equilibrium were excluded. 
 
Genotypes were imputed using ancestry-specific HapMap2,32-34 HapMap3, 1000 
Genomes Phase 1, or 1000 Genomes Phase 3 reference panels (Supplementary Table 
3).35, 36 Genotypes imputed from build 37 of the human genome were lifted over to build 
3637, 38 to enable comparisons between imputation platforms, and all results were 
restricted to SNPs present in HapMap2. 
 
Statistical Analysis 
 
GWA analyses were performed by each cohort separately, and ancestry-specific results 
for each ECG phenotype were combined with meta-analysis. Within each cohort, for 
approximately 2.5 million genotyped or imputed autosomal SNPs, sulfonylurea-SNP 
interactions were estimated with an additive genetic model using mixed effects models, 
GEE, or linear regression with robust standard errors. The analytic model varied based 
on the study design and the availability of longitudinal data (Supplementary Table 4). All 
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analyses were adjusted for age, sex, study site or region, principal components of 
genetic ancestry, visit-specific RR interval (inversely related to heart rate), and visit-
specific use of QT prolonging medications. The QT-prolonging effect of medications 
was categorized as definite, possible, or conditional, according to the University of 
Arizona Center for Education and Research on Therapeutics (UAZ CERT) system of 
classification, and adjusted for as binary variables for each category (presence of any 
versus none).39 HCHS/SOL incorporated estimates of relatedness into all analyses. 
Cohort-specific results were corrected for genomic inflation. 
 
Previous simulations demonstrated that models using robust standard errors 
underestimate the variance of coefficient estimates for SNPs with low MAFs.26 To 
account for this, corrected standard errors were calculated using a t distribution as the 
reference distribution. Cohort and SNP-specific degrees of freedom (df) for the t 
distribution were estimated primarily using Satterthwaite’s method.40 For cohorts unable 
to implement Satterthwaite’s method, an approximate df was calculated as two times 
the cohort- and SNP-specific product of the SNP imputation quality (0-1), MAF (0.00-
0.50), and Nexposed. Standard errors were then corrected by assuming a normal 
reference distribution that yielded the t distribution-based P values from the coefficient 
estimates. Furthermore, because simulations demonstrated that corrected standard 
errors were unstable when minor allele counts among the exposed were low, an 
approximate df filter of 10 was applied to cohort-specific results across all SNPs. 
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Primary analyses: For each ECG phenotype and for each ancestral population, SNP-
by-treatment interaction coefficients and corrected standard errors were combined with 
inverse-variance weighted meta-analysis using METAL.41 SNPs had to meet quality 
control criteria and pass the df filter in at least two studies to be included. The threshold 
for statistical significance was P < 5x10-8, which has been used in other GWA studies of 
correlated phenotypes.42, 43 For each locus with multiple SNPs meeting the threshold for 
statistical significance, a lead SNP with the lowest P value was identified. Significant loci 
and loci at suggestive levels of statistical significance (P < 10-6) were annotated using 
information from several genomics and bioinformatics databases. RefSeq genes within 
500 kb of lead SNPs were identified from the UCSC Genome Browser.44 The NHGRI-
EBI GWAS Catalog was queried for other traits associated with lead SNPs in GWA 
studies.45 HaploReg (Broad Institute) was queried to identify missense coding variants 
in linkage disequilibrium (LD) (R2 < 0.8) with lead SNPs.46 Cis-expression quantitative 
trait loci (cis-eQTLs) in LD with lead SNPs were identified from several gene expression 
databases, including ScanDB and the Broad Institute GTEx Portal, that include samples 
from multiple cell lines and tissue sites, including whole blood, leukocytes, 
subcutaneous adipose, skeletal muscle, lung, skin, fibroblasts, arterial wall, and left 
ventricular and atrial heart tissue.47 
 
Secondary analyses: All ancestry-specific summary results were combined in a trans-
ethnic inverse-variance weighted meta-analysis using METAL. Because effects may be 
heterogeneous across different racial/ethnic populations,48, 49 we conducted additional 
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trans-ethnic analyses using the Bayesian MANTRA method, with a genome-wide 
significance threshold of log10(Bayes Factor [BF]) > 6.50 
 
Previous candidate gene pharmacogenetic studies have identified several 
pharmacokinetic and pharmacodynamic loci for sulfonylurea-associated glucose-
lowering effects and hypoglycemia.19-23, 51-54 Also, large-scale GWA studies have 
identified 35 replicated genetic loci for QT interval main effects.18 For these candidate 
SNPs, the P value threshold for statistical significance was 0.05 divided by the total 
number of tests conducted across all ECG phenotypes and populations: 0.05 / 158 = 
3.2 x 10-4. 
 
For the QT interval, we also assessed for enrichment of candidate SNP-by-treatment 
interactions with a high probability of being functional for cardiac conduction and 
repolarization phenotypes. SNPs that fell within 50 kb of transcripts that are 
preferentially expressed in the left ventricle were identified using the GTEx database 
(839 transcripts). SNPs in these gene regions were filtered to those falling within DNAse 
I hypersensitivity, H3K4me3 or CTCF chip-seq peaks assayed in human 
cardiomyocytes from the NIH Roadmap Epigenomics Consortium 
(http://www.roadmapepigenomics.org). Additionally, SNPs that were eQTLs in left 
ventricle tissue (P < 1 x 10-10) were selected.55, 56 All variants were pruned using 
ancestry-matched LD patterns from the 1000 Genomes project at a level of R2 > 0.5,57  
resulting in 9 004, 8 424 and 5 437 candidate SNPs for EA, AA and HA analyses 
respectively. The P value threshold for statistical significance for these candidate SNP 
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analyses was 0.05 divided by the total number of SNPs selected (P < 5.6 x 10-6 for EA, 
P < 5.9 x 10-6 for AA, and P < 5.6 x 10-6 for HA). The selection of candidate SNPs was 
validated by evaluating enrichment for low P value variants using main-effect SNP 
associations from the QT Interval-International GWAS Consortium.58   
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RESULTS 
 
Characteristics of the 11 cohorts and 21 ancestry-specific analysis populations are 
listed in Table 1. There were 45 002 EA participants (Nexposed 2 095 [4.7%]), 11 731 AA 
participants (Nexposed 1 167 [9.9%]), and 15 124 HA participants (Nexposed 794 [5.2%]), for 
a total of 71 857 (Nexposed 4 056 [5.6%]). Mean durations of ECG intervals ranged from 
397 to 414 ms for QT, 300 to 325 ms for JT, and 85 to 98 ms for QRS. The correlation 
between traits was evaluated among EA and AA participants of CHS: QRS and JT were 
highly correlated (R2 > 0.5), while QRS was not correlated with either QRS or JT (R2 < 
0.1). 
 
Primary analysis results 
 
Sulfonylurea-SNP interaction results from cohort-specific GWA analyses were well-
calibrated: genomic inflation factors for ancestry-specific meta-analyzed results ranged 
from to 0.97 to 1.04 (Supplementary Table 5). A total of 31 sulfonylurea-SNP interaction 
associations met the genome-wide threshold for significance, comprising 8 unique loci 
(Figure, Table 2). Each of the 8 loci was significant for only one of the three ECG 
phenotypes (2 QT, 5 JT, 1 QRS) and in only one racial/ethnic population (3 EA, 5 AA); 6 
were low frequency variants (MAF ≤ 5%). Absolute values for effect sizes ranged from 4 
to 16 ms. All loci were intergenic and none had substantial LD with coding variants. 
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The TM2D1-NFIA locus (rs1890262) on chromosome 1 was approximately 200 kb away 
from a locus associated with QRS interval main effects; NFIA encodes a transcription 
factor of unknown significance for cardiac tissue development.59 A locus on 
chromosome 2 (rs12468579) was 2 kb away from GLS and was also identified as a cis-
eQTL for GLS and MFSD6 transcripts in blood, lung, and prostate;60-63 GLS encodes 
glutaminase, which catalyzes the production of glutamine, the most abundant excitatory 
neurotransmitter in the central nervous system.64 The chromosome 3 locus (rs1478173) 
was approximately 115 kb away from a locus for coronary artery disease.65 The only 
locus associated with another trait (periodontitis) in a previous GWA study was 
rs9966832 near SS18 on chromosome 18.66 
 
Among the 37 suggestive associations (P value < 10-6 but > 5 x 10-8) (Supplementary 
Table 6), 15 (41%) were intronic, one was a missense variant, three were in LD (r2 > 
0.8) with missense variants, and five were cis-eQTLs in multiple tissues. Several of the 
sub-threshold loci were located in or near genes that might be relevant to cardiac 
conduction, repolarization, or arrhythmogenesis. For example, rs6035275 is an intronic 
SNP in SLC24A3, a potassium-dependent sodium/calcium ion exchanger that plays a 
role in calcium homeostasis,67 and rs624896 is located 24 kb away from KCNN2, a 
voltage-independent calcium-activated potassium channel that helps to regulate 
neuronal electrical conduction.68 
 
Secondary analysis results 
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Trans-ethnic fixed effects meta-analyses and MANTRA analyses did not identify any 
additional loci (results not shown). Among the candidate SNPs, only one was 
significantly associated with an ECG phenotype when multiple comparisons were 
accounted for (Table 3). This SNP, rs1057910 (Ile359Leu), is a loss of function variant 
that defines the *3 haplotype of CYP2C9, a highly polymorphic cytochrome P450 (CYP) 
enzyme that metabolizes 15-20% of all known drugs that undergo phase I oxidative 
metabolism.69 For the sulfonylurea-SNP interaction, the minor allele of rs1057910 was 
associated with a 7.6 ms (standard error [SE] 2.1 ms) decrease in the QT interval (P = 
2.3 x 10-4) in HA cohorts (MAF 0.05), but not in EA cohorts (MAF 0.07). This SNP did 
not meet filtering criteria for meta-analysis in the AA cohorts. The more common 
functional variant (rs1799853) that defines the *2 haplotype of CYP2C9 (MAF 0.13 in 
EA, 0.09 in HA) was also evaluated, but it was not significantly associated with any of 
the ECG phenotypes. 
 
Selecting additional candidate SNPs based on bioinformatic analysis of annotation from 
cardiac gene expression and regulatory marks active in cardiomyocytes did not identify 
additional loci.  While these variants were enriched for signals among main-effects QT 
analyses (Supplemental Figure 1), none met our statistical significance threshold for 
sulfonylurea-SNP interactions with the QT, JT or QRS intervals (Supplemental Figure 
2). 
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DISCUSSION 
 
In this study, we identified eight novel loci for sulfonylurea-genetic interactions with the 
QT, JT, and QRS intervals. For seven of these pharmacogenomic associations, the 
effect size was > 5ms, the threshold for regulatory concern established by the FDA. 
Compared to our previous effort, which included 869 sulfonylurea users among 
approximately 30 000 EA participants and failed to identify any genome-wide significant 
loci, this effort included over 4 000 sulfonylurea users among over 70 000 participants 
from diverse ancestries. Broadening the racial/ethnic composition of the study 
population and extending our investigation to related ECG phenotypes improved our 
ability to identify pharmacogenomic loci; most were identified in AA populations and for 
the JT interval.  
 
Some of the novel pharmacogenomic loci discovered in our study were near (but not in 
LD with) loci for related traits, such as the NFIA locus for QRS interval main effects59 
and a locus on chromosome 3 for coronary artery disease.65 None of the eight loci were 
near genes that have a clear role in cardiac conduction or repolarization, and even with 
the use of several bioinformatics resources, the biologic mechanism that would explain 
these drug-gene interactions are unknown. Among the loci that did not meet the 
genome-wide threshold for statistical significance but had a P value < 10-6, several were 
located in or near potassium ion channels or ion exchanger genes involved in electrical 
conduction. Without rigorous statistical evidence to support these sub-threshold 
associations, however, their validity is uncertain and replication is needed. 
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We also assessed candidate SNPs involved in the pharmacokinetics and 
pharmacodynamics of sulfonylureas and SNPs associated with the QT interval in main 
effects GWA analyses. Among these SNPs, only a well-known functional variant in 
CYP2C9 was identified as a pharmacogenomic locus for sulfonylureas. Variant 
rs1057910 (CYP2C9*3) reduces the catalytic activity of CYP2C9, the main CYP 
isoenzyme involved in the metabolism of sulfonylureas,69, 70 and this variant has been 
associated with severe skin reactions from phenytoin use71 and warfarin-related 
hemorrhage.72, 73 Previous studies have evaluated the impact of CYP2C9 functional 
variants on sulfonylurea-related treatment response and adverse effects: in one study, 
the presence of either the CYP2C9*2 or the CYP2C9*3 haplotype was associated an 
increased reduction in hemoglobin A1c and an increased probability of achieving 
adequate glycemic control,19 and in another study these variants were associated with 
an increased risk of hypoglycemia among elderly persons.74 
 
In our study, variant rs1057910 was associated with a shorter QT interval. This was a 
surprising finding, because reduced function variants in CYP2C9 decrease the 
clearance of sulfonylureas,70 which would be expected to prolong the QT interval. A 
short QT interval, which can be hereditary or acquired, has been associated with 
cardiac arrhythmias and an increased risk of death.75-77 Various drugs can also shorten 
the QT interval, and whether drug-induced shortening of the QT interval causes cardiac 
arrhythmias is an area of debate.78 Although many pharmacogenomic findings for 
diabetes drugs23, 24 and for other types of drug therapies79, 80 have failed to replicate in 
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the past, there is now a growing body of evidence that rs1057910 may be a genuine 
pharmacogenomic locus for sulfonylureas. Whether this variant contributes to the 
increased cardiovascular risk associated with sulfonylureas in a subset of the population 
is uncertain. 
 
Strengths of our study include repeated high-quality phenotype measurements recorded 
from ECGs conducted at study visits, a large sample size, and the inclusion of diverse 
ancestry populations. There were also several limitations. With the exception of the two 
cohorts from the Rotterdam Study, medication use was assessed with the inventory 
method,81 and some participants classified as sulfonylurea users may have failed to 
take the medication on the day of the study visit. However, changes in diabetes 
medications typically occur over a period of months or years rather than weeks, and this 
type of misclassification would bias associations toward the null, decreasing power to 
identify pharmacogenomic associations. By the same rationale, this type of 
misclassification is expected to decrease rather than increase the chance of false 
positive findings.  
 
Because all available analysis populations from the CHARGE consortium were included 
in a single-stage discovery analysis, which is a more powerful approach than a two-
stage approach that includes separate discovery and validation samples,29, 30 there was 
no opportunity to assess the validity of our findings through replication in independent 
study populations. The increasing availability of electronic health data and the 
decreasing cost of genotyping has led to the emergence of a new model for genomic 
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discovery research: biobanks that link genetic data on tens or even hundreds of 
thousands of individuals with prescription records and other electronic health data to 
create large data repositories. Some biobank studies, such as the UK Biobank82, have 
conducted ECGs as a part of study visits, while others83 may have access to ECGs 
obtained through clinical care. Although the large sample sizes in these biobank studies 
may be attractive for pharmacogenomics research, results from ECGs and other clinical 
tests that are conducted during the course of clinical care may be related to the 
indication for conducting the test, which can result in confounding and false positive 
associations. 
 
In conclusion, we have identified several novel loci for sulfonylurea-related changes in 
various ECG phenotypes in a large multi-site pharmacogenomics study conducted 
within the CHARGE consortium. Although these findings may explain some of the 
cardiovascular risk associated with sulfonylureas for some individuals, replication in 
independent study populations is necessary and further work is needed to determine 
the genetic and biologic mechanisms of these drug-gene interactions.   
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Table 1. Characteristics of study populations 
Cohort N Nexposed (%) Age, y (SD) Female, N (%) 
QT interval, 
ms (SD) 
JT interval, 
ms (SD) 
QRS interval, 
ms (SD) 
European Ancestry        
AGES 2 587 64 (2.5) 75 (4.7) 925 (64) 406 (34) 316 (33) 90 (10) 
ARIC 8 597 379 (4.4) 54 (5.7) 4 453 (53) 399 (29) 308 (29) 91 (10) 
CHS 3 055 280 (9.2) 72 (5.3) 1 880 (63) 414 (32) 321 (30) 88 (10) 
Health ABC 1 441 81 (5.6) 74 (2.8) 714 (49) 414 (32) 324 (32) 90 (11) 
MESA 2 256 71 (3.1) 62 (10.1) 1 156 (52) 412 (29) 320 (29) 93 (9) 
NEO 5 366 94 (1.8) 56 (5.9) 2 521 (47) 406 (29) 313 (29) 93 (10) 
PROSPER 4 555 243 (5.3) 75 (3.3) 2 445 (47) 414 (36) 320 (35) 94 (11) 
Rotterdam 1 4 805 216 (4.5) 69 (8.6) 2 891 (60) 397 (29) 300 (28) 97 (11) 
Rotterdam 2 1 889 84 (4.4) 65 (7.6) 1 070 (57) 403 (28) 305 (28) 98 (11) 
WHI GARNET 3 943 304 (7.7) 66 (6.8) 3 642 (100) 400 (32) 314 (31) 86 (9) 
WHI MOPMAP 1 324 36 (2.7) 63 (6.6) 1 224 (100) 402 (30) 316 (30) 86 (8) 
WHIMS 5 184 243 (4.7) 69 (6.0) 4 811 (100) 401 (30) 315 (30) 86 (9) 
Total 45 002 2 095 (4.7)      
African American        
ARIC 2 191 213 (9.7) 53 (5.8) 1 322 (62) 400 (33) 310 (32) 90 (10) 
CHS 707 141 (20.0) 73 (5.6) 447 (65) 409 (35) 317 (36) 88 (11) 
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Health ABC 1 020 111 (10.9) 73 (2.9) 588 (58) 411 (35) 322 (34) 88 (11) 
JHS 2 122 117 (5.5) 50 (11.8) 1 244 (61) 410 (30) 319 (30) 92 (1) 
MESA 1 464 135 (9.2) 62 (10.0) 796 (54) 410 (32) 319 (31) 91 (10) 
WHI SHARe 4 227 450 (10.6) 61 (6.8) 3 860 (100) 401 (34) 316 (33) 85 (9) 
Total 11 731 1 167 (9.9)      
Hispanic/Latino        
HCHS/SOL 12 024 518 (4.3) 46 (13.8) 7 155 (60) 416 (28) 325 (29) 91 (10) 
MESA 1 316 134 (10.2) 61 (10.3) 681 (52) 409 (30) 318 (30) 91 (10) 
WHI SHARe 1 784 142 (7.9) 60 (6.4) 1 627 (100) 402 (30) 316 (30) 86 (9) 
Total 15 124 794 (5.2)      
Total, all ancestries 71 857 4 056 (5.6)      
 
N
exposed
=
ni
1+ ni -1( ) rˆ
# Eit = 1{ }
ni
i
å . ms = milliseconds, SD = standard deviation, y = years. Study abbreviations: AGES = Age, 
Gene/Environment Susceptibility – Reykjavik Study, ARIC = Atherosclerosis Risk in Communities Study, CHS = Cardiovascular Health Study, 
Health ABC = Health, Aging, and Body Composition Study, HCHS/SOL = Hispanic Community Health Study/Study of Latinos, JHS = Jackson 
Heart Study, MESA = Multi-Ethnic Study of Atherosclerosis, NEO = Netherlands Epidemiology of Obesity, PROSPER = Prospective Study of 
Pravastatin in the Elderly at Risk, Rotterdam 1 = first cohort of the Rotterdam Study, Rotterdam 2 = second cohort of the Rotterdam study, WHI 
GARNET = Women’s Health Initiative Genome-wide Association Research Network into Effects of Treatment, WHI MOPMAP = Women’s Health 
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Initiative Modification of Particulate Matter-Mediated Arrhythmogenesis in Populations, WHI SHARe = Women’s Health Initiative SNP Health 
Association Resource, WHIMS = Women’s Health Initiative Memory Study.  
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Table 2. Summary of significant sulfonylurea-SNP interaction associations with QT, JT, and QRS intervals from ancestry-specific 
GWAS meta-analyses (P < 5 x 10-8) 
Lead SNP 
Chr:position 
(hg19) 
Nearest gene Race Studies 
Min/alt 
alleles 
MAF Effect SE P Function 
Other 
GWAS 
Coding 
eQTL 
(P<5x10-8) 
QT interval 
           
  
  rs9966832 18:23405188 SS18 EA 3 G/A 0.03 -10.4 1.9 2.3E-08 Intergenic Periodontitis66   
  rs830233 5:165403746 
 
AA 4 A/G 0.05 -16.3 2.3 2.5E-12 Intergenic    
JT interval 
          
   
  rs1890262 1:62114402 TM2D1,NFIA EA 2 A/G 0.03 14.9 2.6 1.8E-08 Intergenic    
  rs12468579 2:191832264 GLS,STAT1 AA 6 G/A 0.49 4.1 0.8 4.5E-08 Intergenic   GLS60-63, MFSD660 
  rs1478173 3:162276405 
 
AA 2 C/A 0.03 -15.0 2.1 1.0E-12 Intergenic    
  rs17281245 4:182635289 TENM3 AA 5 C/T 0.06 8.8 1.5 5.4E-09 Intergenic    
  rs7713675 5:28750307 LSP1P3 AA 4 C/T 0.05 -12.2 2.1 9.8E-09 Intergenic    
QRS interval 
          
   
  rs7595140 2:71551621 ZNF638,PAIP2B EA 4 G/C 0.03 -5.7 1.0 3.8E-08 Intergenic    
 
EA = European ancestry, AA = African American, HA = Hispanic/Latino ancestry, MAF = minor allele frequency, SE = standard error. Studies = 
number of cohorts contributing to ancestry-specific analysis. Other GWAS = phenotypes associated with lead SNP (P < 5 x 10-8) in other genome-
wide association studies. Coding = lead SNP in linkage disequilibrium (r2 > 0.8) with a protein coding variant. eQTL = transcripts associated with 
SNPs in linkage disequilibrium (r2 > 0.8) with lead SNP.  
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Table 3. Results for pharmacokinetic, pharmacodynamic, and QT main effect candidate SNPs. 
       P values    
 
 
  
QT 
  
JT 
  
QRS 
 
SNP Chr Gene EA AA HA EA AA HA EA AA HA 
Pharmacokinetic  
          
rs105791019 10 CYP2C9 0.42 
 
2.3E-4 0.06 
 
0.55 0.38 
 
4.1E-3 
rs179985319 10 CYP2C9 0.99 
 
0.33 0.81 
 
0.25 0.75 
 
0.62 
Pharmacodynamic  
          
rs1049435551 1 NOS1AP 0.27 0.51 0.89 0.87 0.88 0.62 0.37 0.07 0.74 
rs790314652, 53 10 TCF7L2 0.30 0.94 0.70 0.70 0.44 0.24 0.51 0.89 0.79 
rs1225537252, 53 10 TCF7L2 0.39 0.12 0.71 0.77 0.22 0.50 0.51 0.04 0.86 
rs521523, 54 11 KCNJ11 0.93 0.83 0.57 0.16 0.01 0.84 0.33 0.40 0.76 
rs75711021 11 ABCC8 1.00 0.68 0.47 0.08 2.5E-3 0.60 0.24 0.15 0.66 
QT main effect18  
          
rs2298632 1 TCEA3 0.29 0.88 0.20 0.78 0.89 0.78 0.58 0.87 0.75 
rs846111 1 RNF207 1.00 0.88 0.79 0.82 0.34 0.84 0.64 0.67 0.91 
rs10919070 1 ATP1B1 0.91 
 
0.40 0.25 
 
0.90 0.48 
 
0.35 
rs12143842 1 NOS1AP 0.44 0.88 0.75 0.67 0.29 0.52 0.90 0.49 0.97 
rs295140 2 SPATS2L 0.12 0.54 0.88 0.12 0.42 0.29 0.67 0.83 0.67 
rs938291 2 SP3 0.79 0.41 0.07 0.41 0.10 0.83 0.75 0.58 0.65 
rs7561149 2 TTN-CCDC141 0.85 0.72 0.96 0.84 0.41 0.44 0.43 0.69 0.49 
rs12997023 2 SLC8A1 0.29 0.51 0.61 0.23 0.50 0.15 0.77 0.44 0.22 
rs6793245 3 SCN5A-SCN10A 0.95 0.48 0.55 0.17 0.57 0.85 0.80 0.65 0.94 
rs17784882 3 C3ORF75 0.16 0.26 0.31 0.55 0.91 0.32 0.12 0.40 0.57 
rs3857067 4 SMARCAD1 0.82 0.18 0.46 0.76 0.32 0.81 0.33 0.78 0.41 
rs2363719 4 SLC4A4 0.23 0.72 0.05 0.89 0.95 0.51 0.27 0.84 0.28 
rs10040989 5 GFRA3 0.93 0.70 0.12 0.14 0.12 0.39 0.35 0.82 0.09 
rs7765828 6 GMPR 0.63 0.44 0.23 0.37 0.19 0.05 0.99 0.03 0.40 
rs11153730 6 SLC35F1-PLN 0.84 0.67 0.27 0.24 0.52 0.70 0.45 0.16 0.37 
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rs9920 7 CAV1 0.36 
 
0.01 0.52 
 
0.64 0.08 
 
0.85 
rs2072413 7 KCNH2 0.30 0.88 0.75 0.27 0.38 0.77 0.82 0.70 0.95 
rs1961102 8 AZIN1 0.33 0.22 0.18 0.30 1.00 0.96 0.44 0.51 0.19 
rs11779860 8 LAPTM4B 0.74 0.74 0.08 0.14 0.46 0.65 0.23 0.82 0.16 
rs16936870 8 NCOA2 0.08 0.11 0.96 0.24 0.82 0.16 0.02 0.19 0.54 
rs174583 10 FEN1-FADS2 0.87 0.26 0.98 0.98 0.57 0.16 0.98 0.35 0.48 
rs2485376 10 GBF1 0.86 0.50 0.51 0.03 0.41 0.07 0.13 0.73 0.79 
rs7122937 11 KCNQ1 0.25 0.31 0.11 0.20 0.15 0.38 0.12 0.54 0.29 
rs3026445 12 ATP2A2 0.94 0.29 0.42 0.23 0.81 0.89 0.33 0.28 0.50 
rs728926 13 KLF12 0.30 0.29 0.50 0.46 0.70 0.20 0.75 0.21 0.16 
rs2273905 14 ANKRD9 0.38 0.31 0.16 0.71 0.66 0.50 0.21 0.13 0.09 
rs3105593 15 USP50-TPRM7 0.71 0.89 0.44 0.73 0.91 0.41 0.80 0.35 0.29 
rs735951 16 LITAF 0.34 0.08 0.52 0.28 0.43 0.23 0.59 0.10 0.92 
rs1052536 17 LIG3 0.58 0.70 0.77 0.65 0.67 0.39 0.65 0.40 0.70 
rs246185 16 MKL2 0.11 0.99 0.31 0.81 0.71 0.54 0.32 0.73 0.28 
rs246196 16 CNOT1 0.38 0.96 0.35 0.74 0.97 0.91 0.19 0.60 0.39 
rs1296720 16 CREBBP 0.73 0.32 0.33 0.29 
 
0.29 0.36 
 
0.14 
rs1396515 17 KCNJ2 0.76 0.98 0.78 0.41 0.19 0.64 0.72 0.69 0.64 
rs9892651 17 PRKCA 0.49 0.54 0.29 0.44 0.38 0.98 0.24 0.94 0.37 
rs1805128 21 KCNE1 0.69 
  
0.48 
  
0.36 
  
 
EA = European ancestry, AA = African American, HA = Hispanic/Latino ancestry. With Bonferroni 
correction for 158 tests, the threshold for statistical significance was 3.1 x 10-4. Significant associations 
are bolded. 
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Figure Legends 
Figure. Manhattan plots from each ancestry specific meta-analysis (row) for sulfonylurea-SNP 
interaction associations with each ECG phenotype (column). The dashed line is the genome-
wide threshold for significance (P < 5 x 10-8). The solid line is the threshold for suggestive 
associations (P < 10-6). SNPs with P values < 10-10, outside of the range of the Y axis, are 
denoted by triangles. 
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